ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non‐Cystic Fibrosis Bronchiectasis (CELEB)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02625246
Recruitment Status : Active, not recruiting
First Posted : December 9, 2015
Last Update Posted : December 7, 2018
Sponsor:
Information provided by (Responsible Party):
Marilyn Glassberg, University of Miami

Brief Summary:
To demonstrate the safety of bone marrow-derived allogeneic human Mesenchymal Stem Cells (hMSCs) in patients with bronchiectasis receiving standard of care therapy, and to explore treatment efficacy

Condition or disease Intervention/treatment Phase
Bronchiectasis Biological: hMSCs Phase 1

Detailed Description:

A Phase 1 investigation will be performed to test the safety of two doses of bone-marrow derived hMSCs (20,000,000 and 100,000,000) administered via peripheral intravenous infusion.

Group 1: 3 subjects will receive a single administration of allogeneic hMSCs: 20 x106 (20 million) cells delivered via peripheral intravenous infusion Group 2: 3 subjects will receive a single administration of allogeneic hMSCs: 1 x108 (100 million) cells delivered via peripheral intravenous infusion Interim safety analysis will be performed four weeks after the 1st subject is enrolled in each cohort. Continued safety and tolerability with review of adverse events (AEs) will be assessed at each visit. Efficacy parameters (pulmonary function tests, lung diffusion capacity, lung volumes, 6-Minute Walk Test (6MWT), and dyspnea/Quality of Life (QOL) questionnaires) will be assessed every 12 weeks until study completion. Clinical laboratory tests to assess safety will be performed at every visit.

High Resolution Computed Tomography (HRCT) scan will be performed at the baseline visit (if not done within three months prior to enrollment) and then at week 24.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 6 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell (hMSC) Infusion in Patients With Non-Cystic Fibrosis Bronchiectasis
Actual Study Start Date : February 4, 2016
Estimated Primary Completion Date : May 2019
Estimated Study Completion Date : December 2020

Arm Intervention/treatment
Experimental: Group 1
3 patients will receive a single administration of allogeneic hMSCs: 20 x106 (20 million) cells delivered via peripheral intravenous infusion
Biological: hMSCs
intravenous infusion of bone marrow-derived allogeneic stem cells
Other Name: allogeneic mesenchymal stem cell

Experimental: Group 2
3 patients will receive a single administration of allogeneic hMSCs: 1 x108 (100 million) cells delivered via peripheral intravenous infusion
Biological: hMSCs
intravenous infusion of bone marrow-derived allogeneic stem cells
Other Name: allogeneic mesenchymal stem cell




Primary Outcome Measures :
  1. Number of Participant with treatment emergent serious adverse events [ Time Frame: Week 4 post infusion ]
    incidence of any treatment-emergent serious adverse events defined as the composite of death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities


Secondary Outcome Measures :
  1. Difference in Colony Forming Units (CFUs) in semiquantitative culture of sputum [ Time Frame: Participants will be followed from 1 week to an expected average of 24 weeks following infusion. ]
    Difference in CFUs in semiquantitative culture of sputum

  2. rate of decline of lung function [ Time Frame: Participants will be followed from 12 weeks to an expected average of 24 weeks following infusion. ]
    difference in absolute decline of forced expiratory volume at one second (FEV1) percent predicted

  3. frequency of acute exacerbations [ Time Frame: Participants will be followed from 12 weeks to an expected average of 48 weeks following infusion. ]
    increased cough and sputum production, fever, new or worsened dyspnea in less than 30 days, new or worsened hypoxemia in the absence of other identifiable causes

  4. reported dyspnea and quality of life assessment [ Time Frame: Participants will be followed from 4 weeks to an expected average of 48 weeks following infusion. ]
    using quality of life tool questionnaire QOL-B version 2

  5. death from any cause [ Time Frame: Participants will be followed for the duration of the trial, which is an expected average of 48 weeks. ]
    death from any cause



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years to 87 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provide written informed consent,
  • be between 30 and 87 years old at the time of signing the Informed Consent,
  • weight over 45 and under 150 kg,
  • have a clinical diagnosis of non-CF bronchiectasis prior to screening,
  • Have had at least 2 exacerbations in the past year as documented by physician office or hospital visits (Use of antibiotics of at least one time in the last year),
  • Show a baseline FEV1 between 25% and 85% predicted and over or equal to 1 L and a baseline diffusion capacity of lung for carbon monoxide (DLCO) over or equal to 30% (corrected for hemoglobin but not alveolar volume),
  • Have a normal Right Ventricular function, as documented by Doppler echo or right heart catheterization,
  • if a female of childbearing potential, agree to abide by contraception rules defined below.
  • Subjects may receive nondrug therapies including oxygen supplementation not greater than 4 Liters per minute and pulmonary rehabilitation.
  • Subjects may be on chronic macrolide or inhaled antibiotic treatment bronchiectasis

Exclusion Criteria:

  • Have HRCT and or surgical lung biopsy results inconsistent with the diagnosis of non-CF bronchiectasis. (Exclusion of emphysema and or diffuse parenchymal disease)
  • be unable to perform any of the assessments required for endpoint analysis (report safety or tolerability concerns, perform Pulmonary Function Tests (PFT) or HRCT, undergo blood draws, read and respond to questionnaire
  • If a female of childbearing potential, have a follicle stimulating hormone (FSH) under 25.8 IU/L
  • be actively treated for an acute infectious exacerbation of bronchiectasis
  • Have an active infection that is not treated
  • Have had active infections occurring within a minimum of 4 weeks of study treatment
  • Be currently on treatment for NTM infections
  • Have had positive sputum cultures for nontuberculous mycobacterial (NTM) within the past 6 months
  • Have a history of drug or alcohol abuse within the past 24 months.
  • Be currently receiving (or have received within four weeks of screening) experimental agents for the treatment of bronchiectasis or have been enrolled in clinical trials within the previous 30 days
  • Be actively listed (or expect future listing) for transplant of any organ.
  • Have clinically important abnormal screening laboratory values.
  • Have a serious comorbid illness that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study.
  • Have any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study.
  • Have known allergies to penicillin or streptomycin.
  • Be an organ transplant recipient.
  • Have a clinical history of malignancy within 5 years (i.e., patients with prior malignancy must be disease free for 5 years), except curatively-treated basal cell carcinoma of skin, squamous cell carcinoma of skin, or cervical carcinoma.
  • Have a non-pulmonary condition that limits lifespan to less than 1 year.
  • Be serum positive for HIV, hepatitis BsAg (surface agent reactive) or Viremic hepatitis C.
  • Have hypersensitivity to dimethyl sulfoxide (DMSO)
  • Be unable to maintain saturated oxygen (SpO2) of more than 93% on room air at sea level at rest) or an SpO2 of more than 88% on room air over 5,000 feet (1524 meters) above sea level at rest.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02625246


Locations
United States, Florida
University of Miami Hospitals & Clinics
Miami, Florida, United States, 33136
Sponsors and Collaborators
Marilyn Glassberg
Investigators
Principal Investigator: Glassberg K Marilyn, MD University of Miami

Publications:
Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med. 2005;12(4):205-9

Responsible Party: Marilyn Glassberg, Professor of Medicine, Surgery, and Pediatrics, University of Miami
ClinicalTrials.gov Identifier: NCT02625246     History of Changes
Other Study ID Numbers: 20150627
First Posted: December 9, 2015    Key Record Dates
Last Update Posted: December 7, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Marilyn Glassberg, University of Miami:
bronchiectasis
mesenchymal stem cell
lung
pulmonary
interstitial lung disease

Additional relevant MeSH terms:
Bronchiectasis
Bronchial Diseases
Respiratory Tract Diseases